1 1 Invasive pneumococcal disease (IPD) surveillance in the South- East Asia Region : Successes and challenges Dr. Pushpa Ranjan Wijesinghe Medical Officer ( Emerging Vaccine Preventable Disease Surveillance) Immunization and Vaccine Development (IVD) WHO - SEARO
17
Embed
Invasive pneumococcal disease (IPD) surveillance in … pneumococcal disease (IPD) surveillance in the South- ... Nepal: ... Annual incidence risk of invasive pneumococcal disease
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
11
Invasive pneumococcal disease (IPD) surveillance in the South-
East Asia Region : Successes and challenges
Dr. Pushpa Ranjan Wijesinghe Medical Officer ( Emerging Vaccine Preventable Disease
Surveillance)Immunization and Vaccine Development (IVD)
WHO - SEARO
22
WHO supported Invasive Bacterial Vaccine Preventable Disease surveillance network in SEAR
Source: IVD/SEARO
Independent County sites/networks
??
33
1. Decisions were made and plans are underway for introduction of Pneumococcal conjugated vaccine (PCV) in the SEARa. Bangladesh : 2014b. Nepal: 2014 c. Myanmar : 2016
2. Usefulness of locally/regionally/globally generated evidence at the National Technical Advisory Group of Immunization (NTAGI) for decision makinga. Bangladesh : Introduction and selecting PCV10 over PCV 13b. Nepal: Introduction and selecting PCV10 over PCV 13c. Sri Lanka : based on available evidence, decision to introduce was
deferred in 2010 considering other public health priorities d. Myanmar : No surveillance mechanism; Regional and global
evidence use for decision making
Successes : vaccine introduction
44
Successes: Generating evidence from sentinel surveillance data
a. Bangladesh : Annual incidence risk of invasive pneumococcal disease
– 447 per 100000 under five (unadjusted )– 3058 per 100000 under five (adjusted for low sensitivity of cultures)
Conservative estimates of the impact of the PCV 10
b. Sri Lanka : Annual incidence risk of invasive pneumococcal disease
– 40.9 (95% CI- 29.4-54.5 ) per 100000 under five (unadjusted)– 204.3(95% CI - 177.9-233.3 ) per 100000 under five (adjusted for low
sensitivity of cultures) Estimates of direct medical cost for different outcomes Estimates of cases, DALYs and medical cost prevented by
immunizing with PCV 7. Estimates of cost-effectiveness and incremental cost effectiveness
ratio of PCV-7 introduction
55
Transparent decision making processes through NTAGIs:Bangladesh/Nepal Reviewing surveillance data for introduction
Myanmar Reviewing global and regional evidence forintroduction
Sri Lanka Reviewing surveillance data for priority setting
India Demanding solid, representative evidence base
Country owned /financed networks of surveillance:
India 11 sentinel sites( five to be added)
Bhutan 3 regional sites , 1 district site, Reference lab in Bangkok
Coverage of detected serotypes by PCV types 2009-2012
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Nepal Sri Lanka Bangladesh
OthersPCV13PCV10PCV7
N=35 N=57N=22
Improvement of yield of IPD (1994 to 2012) in Bangladesh with Gradual Addition of Improved Diagnostics (N=1,167)
2754
33 4129 33
13 22 2816
28 30 29 3547
30 28 32 2487
1212
19 13 26 22
30
23 32 1513
3
32
66
77
25 2266
39
12
1
3
3 4
2
1
0
20
40
60
80
100
120
140
160
180 PCR ICT Latex Culture
LATEX
ICT
PCR
Saha et al J Clin Microbiol 1993, 1997, 1999; 2003; Saha et al Clin Infect Dis, 2009, Saha et al PLoS One 2008, Arifeen et al Clin Infect Dis 2009; Saha et al PLoS One 2012
Slide courtesy : Professor Samir K Saha
Unit cost (GAVI) per an enrolled suspected IBVPD case ( US $), 2009-2012
Country Unit cost per an enrolled IBD case ( US$)
2009 2010 2011 2012
Bangladesh 20.4 12.1 19.2 21.4
Nepal (Patan) 70.9 26.6 71.7 159.8
Sri Lanka 49.6 35.6 63.4 144.7
Nepal (Kanti) 19.9 36.6 Surveillance discontinued
USD
Need for higher technical efficiencyIn resource use
1515
Challenges : Supporting networks beyond the WHO support
1. Providing technical support to sentinel sites/laboratories beyond the WHO network
2. Standardization of surveillance , laboratory diagnosis and data management in sites beyond the WHO network
3. Reporting data from other networks to the WHO a. for regional and global decision making
1616
Conclusion1. At the beginning, lack of epidemiological and
economic evidence for priority setting and decision making in SEAR
2. Establishment of sentinel surveillance in the SEAR3. Vaccine introduction decision making using local,
regional and global evidence4. Usefulness of generated evidence, despite the
limited scope of sentinel surveillance5. Potential higher performance and usefulness of the
network with more enthusiastic national interests
1717
Thank you
Is the risk of abandoning the network Without being integrated into existing